Tscan Therapeutics Inc [TCRX] stock prices are down -2.83% to $1.03 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The TCRX shares have gain 14.99% over the last week, with a monthly amount drifted -7.21%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Tscan Therapeutics Inc [NASDAQ: TCRX] stock has seen the most recent analyst activity on November 14, 2025, when Morgan Stanley downgraded its rating to an Equal-Weight. Previously, BTIG Research started tracking the stock with Buy rating on May 16, 2024, and set its price target to $12. On May 13, 2024, Needham initiated with a Buy rating and assigned a price target of $11 on the stock. Wedbush started tracking the stock assigning an Outperform rating and suggested a price target of $8 on June 22, 2023.
The stock price of Tscan Therapeutics Inc [TCRX] has been fluctuating between $0.88 and $3.21 over the past year. Currently, Wall Street analysts expect the stock to reach $7.5 within the next 12 months. Tscan Therapeutics Inc [NASDAQ: TCRX] shares were valued at $1.03 at the most recent close of the market. An investor can expect a potential return of 628.16% based on the average TCRX price forecast.
Analyzing the TCRX fundamentals
The Tscan Therapeutics Inc [NASDAQ:TCRX] reported sales of 8.42M for trailing twelve months, representing a surge of 139.37%. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -20.72%, Pretax Profit Margin comes in at -19.65%, and Net Profit Margin reading is -19.65%. To continue investigating profitability, this company’s Return on Assets is posted at -0.46, Equity is -0.64 and Total Capital is -0.54. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.36.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.0000 points at the first support level, and at 0.9700 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.0600, and for the 2nd resistance point, it is at 1.0900.
Ratios To Look Out For
It’s worth pointing out that Tscan Therapeutics Inc [NASDAQ:TCRX]’s Current Ratio is 6.44. In addition, the Quick Ratio stands at 6.44 and the Cash Ratio stands at 5.41. Considering the valuation of this stock, the price to sales ratio is 6.94, the price to book ratio is 0.41.
Transactions by insiders
Recent insider trading involved Lynx1 Capital Management LP, 10% Owner, that happened on Dec 19 ’25 when 80069.0 shares were purchased. 10% Owner, Lynx1 Capital Management LP completed a deal on Dec 22 ’25 to buy 75500.0 shares. Meanwhile, 10% Owner Lynx1 Capital Management LP bought 6232.0 shares on Dec 23 ’25.
